Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.C. Ahumada, L. Fosbrook, M. Sender, M.A. Casado.
Análisis crítico del artículo: “Análisis farmacoeconómico del tratamiento de la artritis reumatoide resistente a metotrexato con las combinaciones de leflunomida-metotrexato o infliximab-metotrexato” (carta).
Rev Esp Reumatol, 30 (2003), pp. 180-184
[2.]
C. Rubio-Terrés, F.I. Romero, A. Burrell, A. Domínguez-Gil.
Análisis farmacoeconómico del tratamiento de la artritis reumatoide resistente a metotrexato con las combinaciones de leflunomida-metotrexato o infliximabmetotrexato.
Rev Esp Reumatol, 30 (2003), pp. 4-11
[3.]
J.M. Kremer, M. Genovese, G.W. Cannon, J.R. Caldwell, J.J. Cush, M.E. Luggen, et al.
Combination therapy of leflunomide (LEF) and methotrexate (MTX) is effective and well tolerated in rheumaoid arthritis (RA) patients inadequately responding to methotrexate (MTX) alone.
Ann Rheum Dis, 60 (2001), pp. 134
[4.]
Aventis Pharmaceuticals Inc. Evaluation of leflunomide versus placebo for the treatment of active rheumatoid arthritis in subjects receiving a stable dose of methotrexate. Clinical study report N.° K2000CLN0039. HWA 486/4001 (3 de mayo de 2001).
[5.]
J.M. Kremer, M.C. Genovese, G.W. Cannon, J.R. Caldwell, J.J. Cush, D.E. Furst, et al.
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomised, double blind, placebo-controlled trial.
Ann Intern Med, 137 (2002), pp. 726-733
[6.]
C. Rubio-Terrés, A. Domínguez-Gil.
Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with leflunomide in comparison with the combination of infliximab and methotrexate.
J Med Econ, 4 (2001), pp. 19-34
[7.]
D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, D. Furst, C. Goldsmith, et al.
American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis.
Arthritis Rheum, 38 (1995), pp. 727-735
[8.]
D.T. Felson, J.J. Anderson, M.L.M. Lange, G. Wells, M.P. LaValley.
Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?.
Arthritis Rheum, 41 (1998), pp. 1564-1570
[9.]
J. Rovira, F. Antoñanzas.
Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation.
Pharmacoeconomics, 8 (1995), pp. 245-252
Copyright © 2006. Elsevier España S.L. Barcelona
